Skip to content
Government Federal, Medical Health Aged Care

Half a million Australians missing out on cheaper medicines due to outdated systems

Consumers Health Forum 2 mins read

Half a million Australians missing out on cheaper medicines due to outdated systems 

Nearly half a million eligible Australians are missing out on cheaper medicines due to an outdated manual tracking system that should be automated.

The Consumers Health Forum of Australia (CHF) is calling for urgent automation of the PBS Safety Net system after it was revealed 495,865 people who qualified for the benefits in 2024 missed out due to the current paper-based tracking system.

This means almost half a million people are paying more than they should for essential medicine, paying full price for medication when they should have received significant discounts.

“The PBS Safety Net is supposed to protect Australians from high medicine costs, but the reality is too many people don’t even realise they’re eligible,” CEO of CHF Dr Elizabeth Deveny said. 

“We all want to know what benefits we’re entitled to - this should be simple.”

“The current system is failing hundreds of thousands of Australians who simply don’t know it exists, let alone how to track their spending or apply for it.”

The current PBS Safety Net system relies on pharmacists or consumers manually tracking prescriptions, usually requiring people to visit the same pharmacy repeatedly, which is an impractical requirement for many Australians.

“It’s 2025, surely we can do better than using a manual paper-based tracking system. We wouldn’t accept a paper-based system for the Medicare Safety Net, so why do we accept it for the PBS Safety Net?” Dr Deveny said.

“We all know Australians are struggling with the cost of living - fixing this is a no-brainer. We are hearing disturbing accounts of people delaying, skipping or rationing their medication just because they can’t afford it. This leads to poorer health outcomes and higher long-term healthcare costs not only for the consumer but also the healthcare system as a whole. Medicine is essential, and no one should be going without it.”

While concessional PBS Safety Net recipients increased from 1.2 million in 2019 to 2.2 million in 2024, general population recipients actually decreased from 125,964 to 101,605 during the same period.

“We’re worried working families and young professionals who earn just enough not to qualify for concession cards are missing out - simply due to a lack of awareness,” Dr Deveny said.

“Everybody benefits when Australians can afford the medicines they need, and a healthier population means a stronger economy,” Dr Deveny said.

“The government needs to introduce an automated real-time PBS spend tracking system that would automatically apply benefits once consumers hit the threshold, similar to the Medicare Safety Net.”

 

Media contact 

Lauren Ferri 

0422 581 506 

 

Kathleen Ferguson

0421 522 080

More from this category

  • Government Federal, Taxation
  • 08/12/2025
  • 10:11
Australian Taxation Office

ATO returns over $1 billion in unpaid super to employees

The Australian Taxation Office (ATO) has released new data, revealing $1.1billion in unpaid super has been returned to nearly a million individual’s super funds in 2024–25. Deputy Commissioner Ben Kelly said the latest figures show the ATO’s compliance efforts to protect employee’s super entitlements are continuing to pay dividends. ‘We issued over 200,000proactive reminders and prompts, helping more employers stay on track, as well as taking stronger action against those employers who failed to comply.' The ATO raised almost $800million in Superannuation Guarantee Charge (SGC) liabilities, through: 120,000reminders to employers More than 70,000prompts to employers approximately 15,000audit cases. While most…

  • Medical Health Aged Care
  • 08/12/2025
  • 10:11
BeOne Medicines Ltd.

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLL Sonrotoclax in combination with BRUKINSA demonstrated rapid…

  • Contains:
  • Medical Health Aged Care
  • 08/12/2025
  • 09:40
Miltenyi Biomedicine

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease featuresA 12-day manufacturing time resulted in a vein-to-vein time of 14-16 days, reducing the likelihood for bridging therapy.BERGISCH GLADBACH, Germany, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Miltenyi Biomedicine today announced results from the pivotal DALY 2-EU trial evaluating the efficacy and safety of zamtocabtagene autoleucel (zamto-cel) compared with standard chemoimmunotherapy (R-GemOx or Pola-BR) in patients with…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.